Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Clinical Trial Compliance Settlement Relies On Board Oversight

Executive Summary

For a three-year period Merck will inform a committee of its board if trial results are not reported within 12 months; the agreement resolves a shareholder derivative suit claiming Schering directors caused results of the Vytorin ENHANCE trial to be suppressed.

You may also be interested in...

Merck’s Vytorin Litigation Saga Ends With $688 Million Securities Class Action Settlements

Investors alleged they lost money from the nearly two-year delay in release of results of the Enhance trial; Merck and Schering previously paid $5.4 million to states to resolve Enhance investigation.

Another Vioxx Settlement, Another Must-Do List For Merck

Merck has settled Vioxx shareholder derivative litigation by agreeing to implement a host of corporate governance changes. Among the new requirements, Merck must run ads in medical journals publicizing its clinical trial registry, post reviews of its compliance procedures, and create two safety committees

Merck and Schering-Plough Settle Lawsuits Over Vytorin and Zetia Cholesterol Pills

This marks the second time in recent weeks that the drug makers have settled large-scale litigation related to the medicines.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts